The new Covid-19 strain enters China after positive testing returned to the UK

China has detected its first imported case of the new variant of coronavirus that is spreading rapidly in the UK, according to a publication of the Chinese Center for Disease Control and Prevention (CDC). The variant was detected in a 23-year-old woman returning to China from the United Kingdom, which was tested in Shanghai on December 14, according to the latest edition of China CDC Weekly. The case “represents a major potential threat to the prevention and control of Covid-19 in China,” the publication said. Vaccine for the general population Meanwhile, the drug regulator has approved the country’s first coronavirus vaccine for general public use, a sign of confidence in the experimental photographs the nation intends to take inside and beyond its borders. China’s National Medical Administration has authorized a Covid-19 vaccine developed by China National Biotec Group, a state-owned Sinopharm unit, reporters in Beijing said on Thursday. Once approved, the vaccine – which has been authorized for emergency use in China since mid-year, along with other major outbreaks – will be commercially available, meaning it can be given to the general population. US and Singapore regulators have approved shootings in the past month, including vaccines developed by Pfizer, Moderna and AstraZeneca, but these were largely intended for emergency use, a statute China granted to its developers a few months ago. China will target members of the population at higher risk in its vaccinations, including the elderly and those with pre-existing conditions, and then launch the vaccines to the general public, said Zeng Yixin, deputy minister of the country’s National Health Commission. briefing. The country has already given more than 4.5 million doses of the Covid-19 vaccine, with only 3 million given since mid-December, Zeng said. It is said to aim to inoculate 50 million people against the virus by early February, before the annual Lunar New Year celebration. The ratio of side effects, including allergies, is about two in 1 million, Zeng said Thursday. Vaccine for Pakistan Pakistan has decided to pre-reserve 1.1 million doses of Covid-19 vaccine developed by Chinese state-owned Sinopharm, the health ministry said on Thursday, as the number of coronavirus cases reached 479,715 after 2,475 new infections were detected. in the country . China on Thursday granted conditional approval to the country’s first Covid-19 vaccine developed by Sinopharm.

The approval came a day after Sinopharm said its vaccine had shown an efficacy of 79.34% and a positive antibody conversion rate of 99.52% in the intermediate results of phase III clinical trials. The decision to procure the vaccine was taken on Wednesday at a meeting of a special committee of the cabinet, after Sinopharm said its vaccine is 79.34% effective, the Ministry of National Health Services said. The Pakistan Drug Regulatory Authority (Drap) has not yet approved the emergency use of the drug, which, once approved, will be granted free of charge to all front-line health workers in the first quarter of 2021.

Deaths worldwide exceed 1.8 million The global deaths caused by Covid-19 have exceeded 1.8 million even though Tokyo has recorded a record number of new infections, and Japan has warned that it could consider a state of emergency if the new outbreak cannot be contained. Governments around the world have asked their citizens to celebrate the New Year at home. Cities that have spent weeks without new infections, including Beijing and Melbourne, are now reporting groups, and the new highly transmissible virus strain has been found in Singapore and California. The variant is more transmissible and seems to affect a higher proportion of people under the age of 20, according to a report. Bloomberg Modern shows 94.1% efficacy in the UK study: study The results of the primary analysis of the ongoing Phase 3 clinical trial of the Covid-19 vaccine of the American company of Modern Biotechnology revealed the effectiveness of 94.1% of therapeutic treatment in preventing symptomatic infections and severe diseases, according to a study evaluated by colleagues. The study, published Wednesday in The New England Journal of Medicine, found that among more than 30,000 participants randomized to receive the vaccine or a placebo, 11 in the vaccine group developed symptomatic Covid-19, compared with 185 participants who received placebo. . PTI Putin is struggling to sell Russia’s vaccine to the West Russia accuses the West of maligning its achievements in the global race to defeat Covid-19, while its attempts to win key markets for its Sputnik V vaccine meet the demands of regulators. “We understand the game,” Kirill Dmitriev, executive director of the Russian Direct Investment Fund, who supported the development of Sputnik V and negotiated its international launch, said in an interview. “It is a combination of misunderstandings, strong bias and, indeed, very strong efforts to undermine the Russian vaccine.” Bloomberg

Dear reader,

Business Standard has always strived to provide up-to-date information and feedback on developments that interest you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offerings have only strengthened our determination and commitment to these ideals. Even in these difficult times in Covid-19, we continue to be committed to keeping you informed and up-to-date with credible news, authoritative views, and incisive comments on current issues.
However, we have a request.

As we fight the economic impact of the pandemic, we need your support even more so that we can continue to provide you with better quality content. Our subscription model has seen an encouraging response from many of you who have subscribed to our online content. Greater subscription to our online content can only help us reach our goals of providing you with even better and more relevant content. We believe in free, fair and credible journalism. Your support with multiple subscriptions can help us practice the journalism we are dedicated to.

Support quality journalism and subscribe to Business Standard.

Digital editor

Source